A Maine resident is seeking class-action status for a suit accusing Elevance Health of discrimination because it declines to ...
In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab and Uplizna ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 598.51% and ...
Ongoing shortages of popular weight loss and diabetes drugs in the U.S. have spurred fierce competition between established ...
BioAge previously planned to only offer 7.5 million shares at the same price range.The updated SEC filing comes amid a surge of investor interest in a new class of weight loss medications known as GLP ...
Discover an untold biotech story and find out how Pfizer missed an opportunity in the GLP-1 market because of an exit in the ...
Hosted on MSN6h
Is Eli Lilly Stock Still a Buy Near All-Time Highs?Eli Lilly (LLY) stock is trading near its all-time highs, with the shares only about 5% away from the record levels set in ...
While several factors predict sustained glycemic control, predictors of sustained weight control with tirzepatide appear ...
In particular, semiconductor specialist Nvidia is viewed as the engine powering the AI vehicle right now. Demand for its most ...
Minnesota clinics are starting to receive free or low-cost insulin from Eli Lilly and Sanofi. This comes after the Minnesota ...
Some counterfeits contain bacteria and have high impurity levels or different chemical structures to FDA-approved medicines.
Kisunla (donanemab) is the second in a new generation of amyloid-targeting medicines to reach the Japanese market after Eisai ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback